Form 4: Precigen CFO Granted Significant Stock Options as Long-Term Incentive

Precigen's Chief Financial Officer, Harry Thomasian Jr., was granted 350,000 stock options with an exercise price of $1.37, vesting over four years.

Summary

• Harry Thomasian Jr., the Chief Financial Officer of Precigen, Inc. (PGEN), acquired 350,000 derivative securities in the form of options to purchase common stock.
• The transaction date for this grant was May 23, 2025.
• Each option has an exercise price of $1.37 per share.
• The options will vest 50% on May 23, 2026, with the remaining portion vesting in equal monthly installments over the subsequent three years.
• The options have an expiration date of May 23, 2035.
• Following this transaction, Mr. Thomasian directly beneficially owns 350,000 derivative securities.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally viewed positively as it aligns management's long-term interests with shareholder value, indicating confidence in future performance. However, this filing does not contain operational or financial performance data, limiting a broader sentiment assessment.

Positives

• The grant of 350,000 stock options to the Chief Financial Officer aligns management's interests with shareholder value creation, incentivizing long-term performance.
• The options have a long expiration date of May 23, 2035, providing a sustained long-term incentive for the executive.

Negatives

• No direct negative financial implications are immediately apparent from this Form 4 filing, which primarily reports an equity grant.

Risks

• The value of the granted options is subject to the future performance of Precigen's common stock, posing a market risk to the recipient.
• Dilution risk for existing shareholders if all options are exercised when the stock price is above the exercise price.

Future Outlook

This filing does not provide a general future outlook for the company's operations or financial performance. However, the grant of long-term stock options to a key executive implies a strategic intent to incentivize sustained performance and align the CFO's interests with the company's long-term growth trajectory.

Management Comments

• This Form 4 filing is a regulatory disclosure of an equity transaction and does not contain direct management comments or quotes from Harry Thomasian Jr. or other Precigen executives.

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industries to incentivize executive performance, attract talent, and align management's interests with long-term company growth and shareholder value creation. Such grants are a standard component of executive compensation packages in the sector.

Comparison to Industry Standards

• Executive compensation structures, including stock option grants, vary widely across the biotechnology sector based on company stage, market capitalization, and performance metrics. This specific grant size and vesting schedule are within typical industry practices for executive incentives, though a direct comparison to specific peer companies would require a detailed compensation analysis of similar-sized biotech firms and their executive incentive programs.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are disclosed in this Form 4 filing.

Related Party Transactions

• The grant of stock options to the Chief Financial Officer, Harry Thomasian Jr., constitutes a related-party transaction as it involves an executive of the company receiving compensation in the form of equity.

Stakeholder Impact

• Shareholders: The grant of options aims to align the CFO's interests with shareholder value, potentially leading to improved long-term performance and strategic decision-making.
• Employees: While not directly impacting all employees, executive compensation practices can influence overall company culture and incentive structures, potentially setting a precedent for performance-based rewards.

Next Steps

• Monitoring the vesting of the granted options, with 50% vesting on May 23, 2026, and the remainder monthly over the subsequent three years.
• Potential future exercise of these options by the CFO, subject to stock price performance relative to the exercise price and vesting conditions.

Key Dates

Keywords

Precigen, PGEN, stock options, Form 4, insider transaction, executive compensation, Harry Thomasian Jr., equity grant